New Opportunities For VC-Backed Life Sciences Cos.

Law360, New York (June 5, 2013, 1:04 PM EDT) -- The insatiable funding requirements of early-stage life sciences companies demand an unending and time-consuming quest for capital. Inevitably, the path leads to the door of venture capital firms, which have been a traditional source of financing for drug discovery, drug development, diagnostics and other capital-intensive life sciences businesses. However, the bar to raising venture capital, as well as the cost of that capital, continues to rise.

As a result, companies are devoting ever-increasing efforts to secure alternative nondilutive sources of funding from governmental agencies, patient advocacy...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.